Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Interviews

Set Alert for Interviews

‘Challenges Ahead’ For Cell And Gene Therapy, Notes Catapult’s New Chairman McCubbin

The ex-GSK supply head Ian McCubbin will join the independent UK organization aimed at advancing cell and gene therapies, but notes issues with scale and manufacturing ahead.

Executive Changes Personalized Medicine

Life After NASH For CymaBay: An Interview With CEO Sujal Shah

With up to $100m from Abingworth and a recent $75m FOPO, CymaBay has runway to await pivotal data in primary biliary cholangitis in 2023 for seladelpar, after the candidate failed in NASH. It sees a significant market opportunity in the second-line setting cornered by Intercept.

Companies Business Strategies

Bayer Pharma R&D Head Tackles Challenge Of Prioritizing Promising Assets

Nearly a year into the job, research chief Christian Rommel tells Scrip he is impressed with Bayer's arm's length approach to running acquired firms like AskBio and BlueRock and the task ahead is to deliver on the potential they offer, while getting later-stage projects across the approvals finishing line.

Leadership Clinical Trials

MIG Capital: BioNTech Has Transformed Global View Of German Biotech 'But We Don’t Walk On Water’

MIG Capital’s Matthias Kromayer looks back at the huge success of its long-term backing of BioNTech and discusses the group’s next big life sciences investments, but warns that realism and hard work are needed to achieve another breakthrough.

Commercial Companies

Novartis Sneaks Ahead Of Sanofi To Buy Gyroscope

The Swiss giant is paying up to $1.5bn upfront to get hold of Gyroscope's AAV2-based one-time investigational gene therapy for geographic atrophy, an advanced form of dry AMD that leads to irreversible vision loss.

Ophthalmic M & A

Ocugen CEO Musunuri On Gene Therapy Candidates, The Omicron Advantage

Ocugen’s mutation-agnostic candidate for retinitis pigmentosa and leber congenital amaurosis is set for Phase I trials in the US. In this exclusive audio interview, founder and CEO Shankar Musunuri speaks to Scrip about seeking partners beyond CanSino Biologics for the candidate while stressing Bharat Biotech’s COVID-19 vaccine could hold promise against the Omicron variant.

Research & Development Coronavirus COVID-19

How Novartis Is Tailoring Its Strategy In Asia Pacific, Middle East and Africa

Iris Zemzoum, Novartis Pharma's president for Asia Pacific, Middle East and Africa, outlines how the company is shaping its strategy in the region, which comes with “extremes” in market profiles, via a distinct archetype that factors in commonalities between national healthcare systems. The company is also progressing interesting initiatives in digital therapeutics.

Commercial Coronavirus COVID-19

AstraZeneca And BenevolentAI Advance AI Partnership With Second Novel Target

AstraZeneca and BenevolentAI claim their partnership is augmenting and accelerating validation of new drug targets.

Respiratory Renal

Parexel Exec Says Non-COVID-19 Drug Discovery Back With A Bang

Clinical trial initiations in cell and gene therapies and immuno-oncology are seeing a spike as the COVID-19 experience has shown the benefits of beginning research early, Parexel’s executive vice president says. In an interview with Scrip, Sanjay Vyas discusses a range of topics from diversity to the advantages of block chain and growth in China

Research & Development Clinical Trials

Mutation Quirk In NRx’s COVID-19 Vaccine Asset Could Help Fight VOCs

The firm’s live-virus COVID-19 vaccine candidate BriLife is entering a late-stage study following Phase II success, sparking hopes that its spontaneous mutations could parallel those of VOCs.

Vaccines Coronavirus COVID-19

BeiGene Switches To Combo Therapy Approach For Brukinsa

BeiGene exec reveals Chinese firm's changing development strategy around key asset as further clinical results emerge.

China Clinical Trials

Piramal Dreams Big, Wants To Be In Top Five India-Listed Pharma

Nandini Piramal, executive director, Piramal Enterprises, discusses how things have shaped in the group's pharma business, its continuing appetite for acquisitions, efforts to de-risk the supply chain for key starting materials and the outsourcing  "framework" deployed by industry.

Commercial Strategy
See All
UsernamePublicRestriction

Register